1525 O'Brien Drive
About GRAIL, Inc.
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit www.grail.com.
CEO: Hans Bishop
80 articles with GRAIL, Inc.
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, announced the appointment of Satnam Alag, PhD, as Senior Vice President of Software Engineering.
In the midst of a pandemic, oncology-focused companies virtually unveil data at the American Association for Cancer Research (AACR) Annual Meeting.
Findings Demonstrate Strong Performance of GRAIL’s Multi-Cancer Early Detection Blood Test in Patients with Suspicion of Cancer
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced the appointment of Sir Harpal Kumar as President of GRAIL Europe. In this new role, Sir Harpal will be responsible for leading GRAIL’s entry and growth in Europe. “I am delighted to welcome Harpal to the GRAIL team. He is a passionate advocate for better outcomes in cancer, with a widely recognized ap
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced validation data for its multi-cancer early detection blood test were published in Annals of Oncology.
GRAIL Initiates First Interventional Study Using its Multi-Cancer Early Detection Test to Guide Clinical Care
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced the initiation of the PATHFINDER Study.
Mr. Kollu joins GRAIL from Illumina, Inc. where he most recently served as Vice President, Global Market Development and led the teams that drove the commercial adoption of genomics in multiple applications including noninvasive prenatal testing and liquid biopsy.
GRAIL, Inc. announced that Matthew P. Young has been appointed Chief Operating Officer and Chief Financial Officer effective October 28, 2019.
CORRECTING and REPLACING GRAIL Announces Positive Validation Data for Its Multi-Cancer Early Detection Test
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, announced new data validating the performance of its investigational multi-cancer early detection blood test for the first time in an independent cohort of participants.
Results to be Presented at ASCO 2019 Breakthrough Validate Test Performance on an Independent Data Set
A new blood test in development from GRAIL, Inc. and studied by investigators at the Dana-Farber Cancer Institute has the ability to accurately screen for numerous types of cancer.
GRAIL to Present New Data in Late-Breaking Oral Presentation at the European Society for Medical Oncology (ESMO) 2019 Congress
GRAIL, Inc. announced that new data supporting its technology to detect cancer at early stages with a single blood test will be presented as a late-breaking oral presentation at the European Society for Medical Oncology 2019 Congress in Barcelona, Spain.
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced that Rodger Currie, JD, has been appointed Vice President and Head of Government Affairs and Alliance Development.
GRAIL Announces Appointment of Hans Bishop as Chief Executive Officer and Strengthens Leadership Team and Board of Directors with New Appointments
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced that Hans Bishop has been appointed as Chief Executive Officer, effective immediately.
GRAIL, Inc., a healthcare company focused on the early detection of cancer, today announced new data from the Circulating Cell-free Genome Atlas (CCGA) study that demonstrates the ability of GRAIL’s technology to detect cancer early with a single blood test.
GRAIL Announces Promising New Data with Early Detection Blood Test to be Presented at 2019 American Society of Clinical Oncology Annual Meeting
GRAIL, Inc., a healthcare company focused on the early detection of cancer, announced that new findings from its Circulating Cell-free Genome Atlas (CCGA) study will be presented in four poster presentations at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4 in Chicago.
GRAIL Announces Significant Progress with Multi-Cancer Early Detection Test Including FDA Breakthrough Device Designation
Proprietary Methylation Technology Selected for Continued Development of Multi-Cancer Test
Companies are filling in the gaps and the entire area of so-called “liquid biopsies” is hot these days, with companies like Guardant Health, Karius, Freenome, Apostle and GRAIL Bio entering the market. With this backdrop, let’s look at some companies working in the same field as the now-defunct T...
Company Also Announced Promotion of Alex Aravanis to Chief Scientific Officer
GRAIL Announces Plans to Initiate SUMMIT Study to Support Development of Blood Test for Early Cancer Detection
SUMMIT Study Partners Include UCL and University College London Hospitals NHS Foundation Trust in the United Kingdom, and Lung Cancer Alliance